

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

|   |   |   |  |  |
|---|---|---|--|--|
| 1. Name and Address of Reporting Person *<br>CELGENE CORP /DE/<br>(Last) (First) (Middle)<br>86 MORRIS AVENUE<br>(Street)<br>SUMMIT, NJ 07901<br>(City) (State) (Zip) | 2. Date of Event Requiring Statement (Month/Day/Year)<br>09/26/2018 | 3. Issuer Name and Ticker or Trading Symbol<br>SUTRO BIOPHARMA INC [STRO]   |  |  |
|   |   | 4. Relationship of Reporting Person(s) to Issuer<br>(Check all applicable)<br><input type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner<br><input type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) |  | 5. If Amendment, Date Original Filed (Month/Day/Year)  |
|   |   |   |  | 6. Individual or Joint/Group Filing (Check Applicable Line)<br><input checked="" type="checkbox"/> Form filed by One Reporting Person<br><input type="checkbox"/> Form filed by More than One Reporting Person |

### Table I - Non-Derivative Securities Beneficially Owned

|                                 |   |  |   |
|---------------------------------|---|--|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
|---------------------------------|---|--|---|

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

### Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 4)        | 2. Date Exercisable and Expiration Date (Month/Day/Year) |                 | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) |                            | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
|---|--|-----------------|---|----------------------------|--|---|---|
|   | Date Exercisable   | Expiration Date | Title   | Amount or Number of Shares |  |   |   |
| Series C-2 Redeemable Convertible Preferred Stock | (1)  | (1)             | Common Stock  | 337,725                    | § (1)  | D   |   |
| Series D Redeemable Convertible Preferred Stock   | (2)  | (2)             | Common Stock  | 115,227                    | § (2)  | D   |   |
| Series D-2 Redeemable Convertible Preferred Stock | (3)  | (3)             | Common Stock  | 758,278                    | § (3)  | D   |   |
| Series E Redeemable Convertible Preferred Stock   | (4)  | (4)             | Common Stock  | 514,967                    | § (4)  | D   |   |

## Reporting Owners

| Reporting Owner Name / Address                            | Relationships |           |         |       |
|---|---------------|-----------|---------|-------|
|   | Director      | 10% Owner | Officer | Other |
| CELGENE CORP /DE/<br>86 MORRIS AVENUE<br>SUMMIT, NJ 07901 |               | X         |         |       |

## Signatures

|   |            |
|---|------------|
| /s/ David Elkins, EVP and Chief Financial Officer | 09/26/2018 |
| **Signature of Reporting Person                   | Date       |

## Explanation of Responses:

\* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Each share of Series C-2 redeemable convertible preferred stock is convertible into 0.0405 share of common stock without payment of further consideration and will automatically convert into 0.0405 share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.

Each share of Series D redeemable convertible preferred stock is convertible into 0.0405 share of common stock without payment of further consideration and will  
(2) automatically convert into 0.0405 share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.

Each share of Series D-2 redeemable convertible preferred stock is convertible into 0.0419 share of common stock without payment of further consideration and will  
(3) automatically convert into 0.0419 share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.

Each share of Series E redeemable convertible preferred stock is convertible into 0.0275 share of common stock without payment of further consideration and will  
(4) automatically convert into 0.0275 share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.